Biogen’s Alzheimer’s drug may only be cost-effective at $2,500 a year

The controversial, but widely anticipated Biogen (BIIB) treatment for Alzheimer’s would only be cost-effective if it is priced between $2,500 and $8,300 a year due to “insufficient” evidence that the drug works, according to a preliminary analysis.

The assessment, which is markedly below some Wall Street estimates of $50,000, reflects the debate over clinical trials that the company submitted to the Food and Drug Administration in hopes of winning approval for its medication. The agency’s closely watched decision about the drug is expected on June 7.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Most Related Links :
Business News Governmental News Finance News

Need Your Help Today. Your $1 can change life.

[charitable_donation_form campaign_id=57167]

Source link

Back to top button